Drug Trial Radar · NCT07370818
To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
81
Planned (sponsor's estimate)
Start
Feb 27, 2026
Primary completion
Dec 31, 2029
Study completion Dec 31, 2031
Sponsor
- Lead sponsor
- Onconic Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to to evaluate the efficacy, safety, and pharmacokinetics of JPI- 547 with bevacizumab maintenance therapy in relapsed ovarian cancer patients
Conditions
- Ovarian Cancer
Interventions
JPI-547Drug
taking JPI-547
BevacizumabDrug
administration Bevacizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Maximum tolerated dose (MTD) and recommended dose (RD)(RP2D)Time frame: The dose-limiting toxicity evaluation window is 21 days
- Part B: Progression free survival(PFS)Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 74 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Severance Hospital, Yonsei Cancer Center, Yonsei University College of Medicine
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.